Novartis (NYSE:NVS) Stock Sold by Rep. Kevin Hern

Key Points

• Rep. Kevin Hern sold between $15,001 and $50,000 of Novartis stock on August 27 through his traditional IRA, according to a disclosure filed September 25. He also reported selling shares of several other companies in September.
• Novartis shares opened at $146.95, with a market capitalization of about $280.4 billion. The company recently reported quarterly revenue of $14.95 billion and earnings of $2.41 per share.
• Analyst sentiment is mixed: six analysts rate Novartis a Buy and ten rate it a Hold, producing an overall Hold consensus and an average price target of $153.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novartis AG NYSE: NVS. In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Novartis stock on August 27th. The trade occurred in the Representative's "KEVIN HERN TRADITIONAL IRA" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of CenterPoint Energy NYSE: CNP on 9/15/2026.
• Sold $1,001 - $15,000 in shares of TJX Companies NYSE: TJX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of STERIS NYSE: STE on 9/15/2026.
• Sold $1,001 - $15,000 in shares of Seagate Technology NASDAQ: STX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Marsh & McLennan Companies NYSE: MRSH on 9/14/2026.
• Sold $15,001 - $50,000 in shares of IQVIA NYSE: IQV on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Emerson Electric NYSE: EMR on 9/14/2026.

Novartis Trading Up 1.0%

NYSE:NVS opened at $146.95 on Tuesday. The stock has a market cap of $280.40 billion, a price-to-earnings ratio of 22.16, a price-to-earnings-growth ratio of 2.81 and a beta of 0.45. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86. The business's 50-day simple moving average is $151.62 and its 200 day simple moving average is $151.15. Novartis AG has a one year low of $121.57 and a one year high of $170.46.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The business had revenue of $14.95 billion during the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. As a group, sell-side analysts predict that Novartis AG will post 8.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on NVS shares. HSBC upgraded Novartis from a "reduce" rating to a "hold" rating and raised their price objective for the stock from $123.00 to $136.00 in a research note on Thursday, September 10th. Citigroup restated a "buy" rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reiterated a "buy (b)" rating on shares of Novartis in a research note on Friday, July 24th. Royal Bank Of Canada began coverage on shares of Novartis in a report on Tuesday, September 8th. They issued a "sector perform" rating on the stock. Finally, Deutsche Bank Aktiengesellschaft lowered Novartis from a "buy" rating to a "hold" rating in a report on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $153.00.

Institutional Trading of Novartis

Large investors have recently modified their holdings of the company. Archer Investment Corp grew its holdings in Novartis by 93.0% in the 1st quarter. Archer Investment Corp now owns 166 shares of the company's stock worth $25,000 after buying an additional 80 shares in the last quarter. Highland Investment Advisors LLC bought a new stake in shares of Novartis in the 2nd quarter worth approximately $25,000. Evolution Wealth Management Inc. lifted its position in shares of Novartis by 552.0% during the 2nd quarter. Evolution Wealth Management Inc. now owns 163 shares of the company's stock valued at $26,000 after acquiring an additional 138 shares during the last quarter. Atlatl Advisers LLC acquired a new position in shares of Novartis in the 2nd quarter valued at $26,000. Finally, Silicon Valley Capital Partners boosted its stake in Novartis by 519.4% in the 2nd quarter. Silicon Valley Capital Partners now owns 192 shares of the company's stock worth $30,000 after purchasing an additional 161 shares during the period. Institutional investors and hedge funds own 13.12% of the company's stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Novartis

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company's research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.

Novartis serves patients and healthcare providers in markets worldwide, with operations spanning North America, Europe, Asia and other international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.